Klin Farmakol Farm. 2025;39(3):171-173 | DOI: 10.36290/far.2025.061

Nitazenes and other opioid receptor superagonists

Jitka Rychlíčková1, 2, Ema Kunová3
1 Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno
2 Fakultní nemocnice u sv. Anny v Brně
3 Farmaceutická fakulta, Masarykova univerzita, Brno

Nitazenes and spirochlorphine are synthetic opioids that have been of interest in recent years in relation to unintentional overdoses with non-fatal and fatal consequences. These substances are potent agonists, predominantly of µ-opioid receptors, and exhibit a similar potency to fentanyl. The diagnosis of overdose is complicated by the inability to detect them with standard opioid screening tests. The available literature on the treatment of nitazene and spirochlorphine intoxication is limited. The objective of this article is to highlight the existence of these agents, summarise the known information on their pharmacology, and point out possible bottlenecks in the diagnosis and treatment of intoxication.

Keywords: nitazenes, spirochlorphine, novel psychoactive substances, naloxone, screening test.

Accepted: October 23, 2025; Published: October 30, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlíčková J, Kunová E. Nitazenes and other opioid receptor superagonists. Klin Farmakol Farm. 2025;39(3):171-173. doi: 10.36290/far.2025.061.
Download citation

References

  1. Pergolizzi Jr J, Raffa R, LeQuang JAK, et al. Old Drugs and New Challenges: A Narrative Review of Nitazenes. Cureus. 2023;15(6):e40736. Go to original source...
  2. Samarasekera U. "Even worse than fentanyls": nitazenes in the USA. The Lancet. 2024;404:2250-2251. Go to original source...
  3. Stahl KD, van Bever W, Janssen P, et al. Receptor affinity and pharmacological potency of a series of narcotic analgesic, anti-diarrheal and neuroleptic drugs. Eur J Pharmacol. 1977;46(3):199-205. Go to original source...
  4. Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11-16. Go to original source...
  5. Shafi A, Berry AJ, Sumnall H, et al. Synthetic opioids: a review and clinical update. Ther Adv Psychopharmacol. 2022;12:12-16. Go to original source...
  6. Stangeland M, Dale O, Skulberg AK. Nitazenes: review of comparative pharmacology and antagonist action. Clin Toxicol (Phila). 2025;63(6):393-406. Go to original source...
  7. Kozell LB, Eshleman AJ, Wolfrum KM, et al. Pharmacology of newly identified nitazene variants reveals structural determinants of affinity, potency, selectivity for mu opioid receptors. Neuropharmacology. 2025;276:110512. Go to original source...
  8. De Vrieze LM, Stove CP, Vandeputte MM. Nitazene test strips: a laboratory evaluation. Harm Reduct J. 2024;21:159. Go to original source...
  9. Caldwell JP, Matasi JJ, Zhang H, et al. Synthesis and structure - activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands. Bioorganic & Medicinal Chemistry Letters. 2007;17(8):2281-2284. Go to original source...
  10. Galzi JL, Mejean A, Ilien B, et al. Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990;33(9):2456-2464. Go to original source...
  11. Berger JC, Severe AD, Jalloh MS, et al. Naloxone Dosing and Hospitalization for Nitazene Overdose: A Scoping Review. J Med Toxicol. 2025;21(2):276-283. Go to original source...
  12. van Dorp ELA, Yassen A, Dahan A. Naloxone treatment in opioid addiction: the risks and benefits. Expert Opin Drug Saf. 2007;6(2):125-132. Go to original source...
  13. Saari TI, Strang J, Dale O. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. Clin Pharmacokinet. 2024;63(4):397-422. Go to original source...
  14. Trøstheim M, Eikemo M, Haaker J, et al. Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade. Neuropsychopharmacol. 2023;48(2):299-307. Go to original source...
  15. Státní ústav pro kontrolu léčiv - Přehled léčiv [Internet]. [citován 13. červenec 2025]. Naloxone Polpharma. Dostupné z: https://prehledy.sukl.cz/prehledy/v1/dokumenty/64230.
  16. Amaducci A, Aldy K, Campleman SL, et al. Naloxone Use in Novel Potent Opioid and Fentanyl Overdoses in Emergency Department Patients. JAMA Netw Open. 2023;6(8):e2331264. Go to original source...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.